You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
This pre-print, based on predictive processing and an energy-based model of cortical dynamics, explores the therapeutic mechanism of serotonergic psychedelics. It suggests that a combination of 5-HT2a and 5-HT1a agonism leads to a more psychologically tolerable acute experience and better therapeutic efficacy compared to pure agonists. This finding supports the clinical success of mixed serotonin agonists like LSD, psilocybin, and DMT, and suggests potential for the development of even more effective and tolerable psychotherapeutic agents, such as biased 5-HT1a agonist psychedelics like 5-MeO-DMT.
This re-analysis of an RCT (n=59) examines the concept of an 'inner healer' effect associated with psilocybin. Participants receiving a high dose of psilocybin (25mg, 2x) reported higher inner healer scores compared to those receiving a placebo (escitalopram). Furthermore, higher inner healer scores in the high-dose group correlated with improved depressive symptoms two weeks post-dosing, suggesting a potential therapeutic mechanism.
Europe explores the future of Psychedelic Medicine in a workshop led by the European Medicines Agency (EMA) - First Day
Psykologvirke offers an intimate learning experience, packed with clinical relevant material including illuminating and deeply moving videos from actual MDMA-sessions.
The Psychedelic Practitioner Foundations Programme by Clerkenwell Health offers a comprehensive intro to psychedelics and psychedelic-assisted therapy for healthcare professionals.
Being Health is a psychiatrist-led mental health practice that leverages the best of psychiatry, novel treatments (ketamine treatments), psychotherapy, functional medicine and wellness services to help people feel better in their everyday state of being.
The Awareness Lectures on Psychedelic Science (ALPS) returns for its fourth edition on 11-12 October 2024 in the city of Aarau, located in the canton of Aargau, Switzerland.
This review (2024) examines the potential therapeutic mechanisms of action for alcoholism (AUD) treatment using 5-MeO-DMT. It highlights that 5-MeO-DMT can induce mystical experiences and ego-dissolution, leading to increased psychological flexibility and mindfulness, which may alleviate AUD symptoms. Additionally, preliminary evidence suggests that 5-MeO-DMT modulates neural oscillations and exhibits neuroplasticity and anti-inflammatory properties, indicating its potential clinical implications for AUD and related psychiatric comorbidities.
The reMind Psychedelics Business Forum will bring together entrepreneurs, business owners, investors, policymakers, and healthcare professionals at the forefront of the rapidly evolving psychedelics marketplace.
This cross-sectional study (n=113) compared experienced psychedelic users (n=56) to nonusers (n=57) regarding neural responses to Self-name stimuli, known for activating self-representation. While no difference in P300 amplitude was found between users and nonusers for Self- or Target-names, users exhibited increased P300 amplitude for Other-names. Additionally, users showed a smaller increase in P300 amplitude for task-relevant stimuli compared to nonusers, suggesting potential alterations in attentional resource allocation rather than prolonged changes in self-representation due to psychedelic use.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
